Ilsung Pharm (003120) - Total Assets
Based on the latest financial reports, Ilsung Pharm (003120) holds total assets worth ₩403.01 Billion KRW (≈ $273.11 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Ilsung Pharm to assess how comfortably operating cash covers total debt obligations.
Ilsung Pharm - Total Assets Trend (2013–2025)
This chart illustrates how Ilsung Pharm's total assets have evolved over time, based on quarterly financial data. See 003120 net assets for net asset value and shareholders' equity analysis.
Ilsung Pharm - Asset Composition Analysis
Current Asset Composition (December 2025)
Ilsung Pharm's total assets of ₩403.01 Billion consist of 67.0% current assets and 33.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 29.9% |
| Accounts Receivable | ₩16.28 Billion | 4.0% |
| Inventory | ₩26.50 Billion | 6.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩2.63 Billion | 0.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Ilsung Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 003120 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ilsung Pharm's current assets represent 67.0% of total assets in 2025, an increase from 37.1% in 2013.
- Cash Position: Cash and equivalents constituted 29.9% of total assets in 2025, up from 1.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 6.6% of total assets.
Ilsung Pharm Competitors by Total Assets
Key competitors of Ilsung Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.39 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Ilsung Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.47 | 26.07 | 12.48 |
| Quick Ratio | 15.75 | 23.35 | 11.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩254.52 Billion | ₩260.10 Billion | ₩250.91 Billion |
Ilsung Pharm - Advanced Valuation Insights
This section examines the relationship between Ilsung Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.39 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 1.5% |
| Total Assets | ₩403.01 Billion |
| Market Capitalization | $92.84 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ilsung Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Ilsung Pharm's assets grew by 1.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ilsung Pharm (2013–2025)
The table below shows the annual total assets of Ilsung Pharm from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩403.01 Billion ≈ $273.11 Million |
+1.54% |
| 2024-12-31 | ₩396.88 Billion ≈ $268.96 Million |
-5.32% |
| 2023-12-31 | ₩419.19 Billion ≈ $284.08 Million |
-15.22% |
| 2022-12-31 | ₩494.42 Billion ≈ $335.06 Million |
+33.13% |
| 2021-12-31 | ₩371.38 Billion ≈ $251.68 Million |
+0.04% |
| 2020-12-31 | ₩371.22 Billion ≈ $251.57 Million |
+0.46% |
| 2019-12-31 | ₩369.52 Billion ≈ $250.42 Million |
+6.41% |
| 2018-12-31 | ₩347.26 Billion ≈ $235.34 Million |
-0.06% |
| 2017-12-31 | ₩347.46 Billion ≈ $235.47 Million |
+2.65% |
| 2016-12-31 | ₩338.50 Billion ≈ $229.40 Million |
-7.77% |
| 2015-12-31 | ₩367.03 Billion ≈ $248.73 Million |
-3.00% |
| 2014-12-31 | ₩378.37 Billion ≈ $256.42 Million |
+1.53% |
| 2013-12-31 | ₩372.66 Billion ≈ $252.55 Million |
-- |
About Ilsung Pharm
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, dige… Read more